Company news
Noxopharm Ltd. (ASX:NOX) news
Noxopharm Ltd. news releases on 6ix. Latest, Aug 5, 2021: Veyonda Survival Advantage in LuPSMA Therapy Confirmed
Press releases — page 3
Veyonda Survival Advantage in LuPSMA Therapy Confirmed
August 5, 2021
June 2021 Quarterly Activities Report and Appendix 4C
July 26, 2021
DARRT-2 Study Receives IND Approval from FDA
June 30, 2021
Noxopharm Secures Key European Patent Allowance for Veyonda
June 29, 2021
DARRT-2 Study Update and Clarification
June 9, 2021
Noxopharm Set to Benefit From Novartis ASCO Data
June 4, 2021
New Independent Trial Data Supports Potential of Veyonda
May 30, 2021
Noxopharm : Veyonda to Begin First-Line Sarcoma Treatment Testing
May 11, 2021
Veyonda FDA Approved Trial to Commence
May 6, 2021
Publications Positive Review of Veyonda in Chemotherapy
April 29, 2021
Noxopharm : Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm
April 27, 2021
March Quarterly Activities Report and Appendix 4C
April 26, 2021
Veyonda Showing Potential to Prevent Cytokine Storm
April 22, 2021
Noxopharm : Files Septic Shock Treatment Patent for Veyonda®
April 14, 2021
Veyonda Patent Lodged for Major Septic Shock Opportunity
April 5, 2021
Noxopharm IONIC Immuno-Oncology Trial Commences
March 18, 2021
NOXCOVID Trial Advances to Final Stage
March 7, 2021
Noxopharm Receives A$4.59M Federal Gov R&D Tax Rebate
March 1, 2021
Company Announcement Regarding Appendix 3Y Disclosures
February 23, 2021
Appendix 4D and Half Year Financial Report
February 15, 2021
LuPIN Survival Outcome Confirmed by Conference Presentation
February 14, 2021
Major Survival Benefit in Prostate Cancer Patients Announced
February 8, 2021
Noxopharm Dec 2020 Quarterly Activities Report & Appendix 4C
January 24, 2021
NOXCOVID Study Advances
January 12, 2021
Pre-Clinical Breakthrough Discovery Set to Expand Pipeline
December 6, 2020
Noxopharm Completes A$23m Placement to Fund Clinical Studies
December 3, 2020
Independent Discovery Validates DARRT Cancer Therapy
November 12, 2020
Veyonda To Be Tested In Combination With Opdivo In Trial
November 8, 2020
Dedicated Septic Shock Company Established
November 5, 2020
Noxopharm Quarterly Activities Report & Appendix 4C
October 14, 2020
Noxopharm Loan Terms Amended to Benefit Company
October 5, 2020
First COVID-19 Patient Treated in Veyonda Study
October 1, 2020
Veyonda COVID-19 Study Approved For Immediate Start
August 31, 2020
Appendix 4E and Audited Financial Statements FY2020
August 30, 2020
Peer-Reviewed Publication Strengthens Case For Veyonda
August 10, 2020
Noxopharm 2020 June quarter Appendix 4C & Activities Report
July 28, 2020
Noxopharm : Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’ Tumors to ‘Hot’
July 23, 2020
Data Shows Idronoxil Holds Key to Problem of COLD Cancers
July 19, 2020
COVID-19 Trial Program to Commence in Europe
June 18, 2020
Pro-rata Non-Renounceable Rights Issue Fully Allocated
June 14, 2020
ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer
May 31, 2020
FDA allows Veyonda Pre-IND Submission for COVID-19
May 19, 2020
Entitlement Offer Prospectus
May 13, 2020
$7.9 Million Fully Underwritten Entitlement Offer Announced
May 12, 2020
Noxopharm March 2020 Quarterly Report & Appendix 4C
April 30, 2020
Abscopal Responses Achieved in Prostate Cancer
April 29, 2020
Pipeline Expands With Potential New Brain Cancer Treatment
April 22, 2020
Approval to be sought for COVID-19 Clinical Study in U.S.
April 20, 2020
Noxopharm Investigating Potential COVID-19 Treatment
March 31, 2020
Veyonda Awarded First Allowed Patent Application
March 16, 2020